logo-loader
viewCytoDyn

CytoDyn stock jumps as investor focus shifts to leronlimab as CymaBay flames out

Vancouver-based CytoDyn's fortunes rose as CymaBay Therapeutics Inc’s NASH ambitions hit a wall

A researcher in a lab
NASH is difficult to diagnose and there are currently no therapies approved by the FDA

CytoDyn Inc (OTCMKTS:CYDY) stock soared Tuesday as investors focused on its lead drug leronlimab in the Non-Alcoholic Steatohepatitis (NASH) space after CymaBay Therapeutics Inc’s (NASDAQ:CBAY) drug seladelpar posted disappointing results in a mid-stage clinical trial linked to NASH.  

NASH is liver inflammation and damage caused by a buildup of fat in the liver. Patients with this disease are often told they have a "fatty liver."

Last month, Vancouver, Washington-based CytoDyn said that the Cleveland Clinic will test its flagship drug leronlimab (PRO 14O) to determine if it can prevent NASH in mice.

CytoDyn stock closed 10.8% higher to $0.44 on the OTC Markets on Tuesday, even as shares in CymaBay tumbled 45.9% to $6.

READ: CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice

The goal of CytoDyn’s exploratory pre-clinical studies by Dr Daniel Linder is to establish leronlimab’s ability to prevent the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) into NASH.

In a separate development, Newark, California-based CymaBay which had enrolled 181 patients with moderate NASH, and treated them for 12 weeks, suffered a setback.

In CymaBay’s Phase 2 study, three oral doses of seladelpar, all performed worse than a harmless placebo, based on a non-invasive imaging test that measures decreases in liver fat.

READ: CymaBay stock bombs after seladelpar disappoints in a study for its liver treatment

If left untreated, NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis, liver failure or liver cancer. CytoDyn said the disease is expected to become the leading cause of liver transplants by 2020.

Despite the growing awareness of NASH, it remains difficult to diagnose and there are currently no therapies approved by the US Food and Drug Administration.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

 

Quick facts: CytoDyn

Price: 0.31 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $120.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read